MMP9 and breast cancer: The same phenomenon can be observed for MMP-9 shRNA loaded on GO modified only with PAMAM, where 10 mg of the carrier system was required to deliver 1 mg of the shRNA in breast cancer cells in vitro and in vivo to cause 52% gene silencing (Figure 3B) [87].